74
S. A. Khan et al.
Andreas Scherer received his Ph.D. in molecular biology at the Max-Planck-Institute for
Immunobiology in Germany. After a postdoctoral position at the UT Southwestern Medical Center in Dallas, USA, until 1999, he has been working on biomarker research in various positions
at Novartis in Basel, CH, from 2000 until 2007. He then worked as consultant and bioinformatician in his own company in Finland, and as Manager of the Bioinformatics Team at the Australian
Genome Research Facility (AGRF) in Melbourne, AU. He is currently working at the Institute for
Molecular Medicine Finland (FIMM) at the University of Helsinki. He is the National Coordinator
for EATRIS ERIC, the European Research Infrastructure for Translational Medicine. He has been
elected co-chair of the EATRIS Biomarker Platform and is chair of the EATRIS Quality Initiative.
He has focused on technological, biological, clinical, and legal, and ethical aspects of personalized
health.
Roland Grafström is a Professor in Risk Assessment at the Karolinska Institutet since 2000.
His speciality is biocomputing and informatics for toxicogenomics, cancer biology, personalized
medicine, and safety-by-design work. It includes mechanistic and mode-of-action-driven modeling and data interpretation related to toxicity effects and adverse outcome pathways. He is also
the CEO of Predictomics AB (SME, Stockholm, Sweden), being a subsidiary to Cercon AB, a
biomedical consulting business in operation since 1983. Customers are trained for using in vitro
and in silico-based predictive workflows based on twenty-first century toxicology and 1R (replacement category) concept, including frequent organization of courses and research guidance for
industry and academia, and developing IPR related to the above fields. He serves on this basis
as science advisor for Misvik Biology Oy, Turku, Finland and BioTeSys GmbH, Esslingen, Germany.
Pekka Kohonen is an assistant Professor in Risk Assessment at the Karolinska Institutet. He is an
expert on toxicogenomics, bioinformatics, and data sciences for toxicology. Interest areas include
integrative omics analyses, high-throughput/high content screening analysis, and Big Data analytics to predict toxicity effects of chemicals and nanomaterials, using primarily cell culture data
(1R). He co-developed with Roland Grafström and others the predictive toxicogenomics space
(PTGS) scoring concept for predicting drug-induced liver injury (DILI). PK is also affiliated with
Predictomics AB (SME, Stockholm, Sweden). Won the 2014 Lush Science prize together with
Prof. Roland Grafström for contributions to twenty-first century Toxicology to replace animal use
in toxicity testing.
S. A. Khan et al.
Andreas Scherer received his Ph.D. in molecular biology at the Max-Planck-Institute for
Immunobiology in Germany. After a postdoctoral position at the UT Southwestern Medical Center in Dallas, USA, until 1999, he has been working on biomarker research in various positions
at Novartis in Basel, CH, from 2000 until 2007. He then worked as consultant and bioinformatician in his own company in Finland, and as Manager of the Bioinformatics Team at the Australian
Genome Research Facility (AGRF) in Melbourne, AU. He is currently working at the Institute for
Molecular Medicine Finland (FIMM) at the University of Helsinki. He is the National Coordinator
for EATRIS ERIC, the European Research Infrastructure for Translational Medicine. He has been
elected co-chair of the EATRIS Biomarker Platform and is chair of the EATRIS Quality Initiative.
He has focused on technological, biological, clinical, and legal, and ethical aspects of personalized
health.
Roland Grafström is a Professor in Risk Assessment at the Karolinska Institutet since 2000.
His speciality is biocomputing and informatics for toxicogenomics, cancer biology, personalized
medicine, and safety-by-design work. It includes mechanistic and mode-of-action-driven modeling and data interpretation related to toxicity effects and adverse outcome pathways. He is also
the CEO of Predictomics AB (SME, Stockholm, Sweden), being a subsidiary to Cercon AB, a
biomedical consulting business in operation since 1983. Customers are trained for using in vitro
and in silico-based predictive workflows based on twenty-first century toxicology and 1R (replacement category) concept, including frequent organization of courses and research guidance for
industry and academia, and developing IPR related to the above fields. He serves on this basis
as science advisor for Misvik Biology Oy, Turku, Finland and BioTeSys GmbH, Esslingen, Germany.
Pekka Kohonen is an assistant Professor in Risk Assessment at the Karolinska Institutet. He is an
expert on toxicogenomics, bioinformatics, and data sciences for toxicology. Interest areas include
integrative omics analyses, high-throughput/high content screening analysis, and Big Data analytics to predict toxicity effects of chemicals and nanomaterials, using primarily cell culture data
(1R). He co-developed with Roland Grafström and others the predictive toxicogenomics space
(PTGS) scoring concept for predicting drug-induced liver injury (DILI). PK is also affiliated with
Predictomics AB (SME, Stockholm, Sweden). Won the 2014 Lush Science prize together with
Prof. Roland Grafström for contributions to twenty-first century Toxicology to replace animal use
in toxicity testing.